Replies to post #150782 on Biotech Values

[DewDiligence]

BIIB—I would venture to guess that Rituxan FOB development by BIIB violates BIIB's contract with Genentech in regards to each party doing what’s in the best interest in the product.

Then how do you explain Samsung—BIIB’s known FoB partner—having been involved in a Rituxan FoB program?

My guess is that the original Idec-Genentech development and commercialization agreement for Rituxan runs out when the master patent on Rituxan expires, so it didn’t preclude BIIB’s participation in developing an FoB that would have come to market after the patent expiration.